Modification of Peptides and Proteins

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 169-191

  Hostrup, Susanne ^a   Huus, Kasper ^a   Parshad, Henrik ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Attachment of lipophilic groups to peptides and proteins; Early drug development phases covering preformulation and formulation; Glucagon like peptide 1 (GLP 1) derivate, liraglutide; Improved delivery via non parenteral delivery routes; Modification of primary structure of peptides and proteins; PEGylated peptides and proteins; Peptides and protein modification; Peptides and proteins; Solid improvements in pharmacokinetics lipophilic groups or PEG chains attachment to proteins; Stability towards interface induced aggregation

Indexed keywords

CONTROLLED DRUG DELIVERY; TARGETED DRUG DELIVERY;

DELIVERY ROUTES; LIRAGLUTIDE; PEGYLATED; PRE FORMULATIONS; PRIMARY STRUCTURES; PROTEIN MODIFICATIONS;

PEPTIDES;

EID: 84865329642     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch9     Document Type: Chapter

References (110)

1. Daly, S.M., Przybycien, T.M. and Tilton, R.D. (2005) Adsorption of poly(ethylene glycol)-modified ribonuclease a to a poly(lactide-co-glycolide) surface. Biotechnol. Bioeng., 90, 856-868.
2. Morar, A.S., Schrimsher, J.L. and Chavez, M.D. (2006) PEGylation of proteins: a structural approach. Biopharm. Int., 19, 34-49.
3. Morpurgo, M. and Veronese, F.M. (2004) Conjugates of peptides and proteins to polyethylene glycols. Methods Mol. Biol., 283, 45-70.
4. Roberts, M.J., Bentley, M.D. and Harris, J.M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev., 54, 459-476.
5. Pasut, G. and Veronese, F.M. (2006) PEGylation of proteins as tailored chemistry for optimized bioconjugates. Adv. Polym. Sci., 192, 95-134.
6. Fee, C.J. and Van Alstine, J.A. (2006) PEG-proteins: reaction engineering and separation issues. Chem. Eng. Sci., 61, 924-939.
7. Harris, J.M., Martin, N.E. and Modi, M. (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet., 40, 539-551.
8. Veronese, F.M. and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discov. Today, 10, 1451-1458.
9. Hinds, K.D. and Kim, S.W. (2002) Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev., 54, 505-530.
10. Sato, H. (2002) Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev., 54, 487-504.
11. Kinstler, O., Molineux, G., Treuheit, M. et al. (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 54, 477-485.
12. Kinstler, O.B., Brems, D.N., Lauren, S.L. et al. (1996) Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res., 13, 996-1002.
13. DeFrees, S., Wang, Z.G., Xing, R. et al. (2006) GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology, 16, 833-843.
14. Caliceti, P., Schiavon, O., Sartore, L. et al. (1993) Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Compat. Polym., 8, 41-50.
15. Goodson, R.J. and Katre, N.V. (1990) Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology, 8, 343-346.
16. Greenwald, R.B., Yang, K., Zhao, H. et al. (2003) Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. Bioconjug. Chem., 14, 395-403.
17. Lee, S., Greenwald, R.B., McGuire, J. et al. (2001) Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins. Bioconjug. Chem., 12, 163-169.
18. Chapman, A.P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev., 54, 531-545.
19. Yamaoka, T., Tabata, Y. and Ikada, Y. (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci., 83, 601-606.
20. Basu, A., Yang, K., Wang, M.L. et al. (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem., 17, 618-630.
21. Harris, J.M. and Chess, R.B. (2003) Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214-221.
22. Chirino, A.J., Ary, M.L. and Marshall, S.A. (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today, 9, 82-90.
23. Hermeling, S., Crommelin, D.J., Schellekens, H. and Jiskoot, W. (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res., 21, 897-903.
24. Bailon, P., Palleroni, A., Schaffer, C.A. et al. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem., 12, 195-202.
25. Wang, Y.S., Youngster, S., Grace, M. et al. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev., 54, 547-570.
26. Mosharraf, M., Malmberg, M. and Fransson, J. (2007) Formulation, lyophilization and solid-state properties of a pegylated protein. Int. J. Pharm., 336, 215-232.
27. Manjula, B.N., Tsai, A., Upadhya, R. et al. (2003) Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug. Chem., 14, 464-472.
28. Rajan, R.S., Li, T.S., Aras, M. et al. (2006) Modulation of protein aggregation by polyethylene glycol conjugation: G-CSF as a case study. Protein Sci., 15, 1063-1075.
29. Stigsnaes, P., Frokjaer, S., Bjerregaard, S. et al. (2007) Characterisation and physical stability of PEGylated glucagon. Int. J. Pharm., 330, 89-98.
30. Wang, W. (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm., 185, 129-188.
31. Wang, W. (2005) Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm., 289, 1-30.
32. Daly, S.M., Przybycien, T.M. and Tilton, R.D. (2005) Adsorption of poly(ethylene glycol)-modified lysozyme to silica. Langmuir, 21, 1328-1337.
33. Daly, S.M., Przybycien, T.M. and Tilton, R.D. (2007) Aggregation of lysozyme and of poly(ethylene glycol)-modified lysozyme after adsorption to silica. Colloid. Surf. B, 57, 81-88.
34. Blundell, T., Dodson, G., Hodgkin, D. and Mercola, D. (1972) Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Prot. Chem., 26, 279-402.
35. Blundell, T. (1983) The conformation of glucagon, in Glucagon I (ed. P.J. Lefé bre), Springer Verlag, Germany, pp. 37-56.
36. Hansen, J.F. (1991) The self-association of zinc-free human insulin and insulin analogue B13-glutamine. Biophys. Chem., 39, 107-110.
37. Brange, J. and Langkjaer, L. (1993) Insulin structure and stability. Pharm. Biotechnol., 5, 315-350.
38. Al-Azzam, W., Pastrana, E.A., King, B. et al. (2005) Effect of the covalent modification of horseradish peroxidase with poly(ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. J. Pharm. Sci., 94, 1808-1819.
39. Castellanos, I.J., Al-Azzam, W. and Griebenow, K. (2005) Effect of the covalent modification with poly(ethylene glycol) on alpha-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres. J. Pharm. Sci., 94, 327-340.
40. Boutin, J.A. (1997) Myristoylation. Cell Signal., 9, 15-35.
41. Roy, M.O., Uppenberg, J., Robert, S.P. et al. (1997) Crystallization of monoacylated proteins: influence of acyl chain length. Eur. Biophys. J., 26, 155-162.
42. Markussen, J. (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia, 39, 281-288.
43. Knudsen, L.B., Nielsen, P.F., Huusfeldt, P.O. et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 43, 1664-1669.
44. Hashimoto, M., Takada, K., Kiso, Y. and Muranishi, S. (1989) Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res., 6, 171-176.
45. Yuan, L., Wang, J. and Shen, W.C. (2005) Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm. Res., 22, 220-227.
46. Wang, J., Chow, D., Heiati, H. and Shen, W.C. (2003) Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release, 88, 369-380.
47. Wang, J., Wu, D. and Shen, W.C. (2002) Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm. Res., 19, 609-614.
48. Ekrami, H.M., Kennedy, A.R. and Shen, W.C. (1995) Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett., 371, 283-286.
49. Wang, J., Shen, D. and Shen, W.C. (1999) Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharm. Res., 16, 1674-1679.
50. Cheng, W., Satyanarayanajois, S. and Lim, L.Y. (2007) Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: Synthesis, characterization and in vivo activity. Pharm. Res., 24, 99-110.
51. Wan, L., Chen, Y.H. and Chang, T.W. (2003) Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification. J. Pharm. Sci., 92, 1882-1892.
52. Kurtzhals, P., Havelund, S., Jonassen, I. et al. (1995) Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J., 312, 725-731.
53. Geiger, R., Obermeier, R., Teetz, V. et al. (1980) Biological activity of insulin analogues substituted at the amino group of B1-phenylalanine, in Insulin Chemistry, Structure and Function of Insulin and Related Hormones (eds D. Brandenburg and A. Wollmer), Walter de Gruyter & Co, Berlin, pp. 409-415.
54. Havelund, S., Plum, A., Ribel, U. et al. (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res., 21, 1498-1504.
55. Whittingham, J.L., Jonassen, I., Havelund, S. et al. (2004) Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins. Biochemistry, 43, 5987-5995.
56. Jonassen, I., Havelund, S., Ribel, U. et al. (2006) Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives . Pharm. Res., 23, 49-55.
57. Klein, O., Lynge, J., Endahl, L. et al. (2007) Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab., 9, 290-299.
58. Heise, T., Nosek, L., Ronn, B.B. et al. (2004) Variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 53, 1614-1620.
59. Kurtzhals, P. (2005) How to achieve a predictable basal insulin? Diabetes Metab., 31, 4S25-4S33.
60. Gutniak, M.K., Linde, B., Holst, J.J. and Efendic, S. (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care, 17, 1039-1044.
61. Arulmozhi, D.K. (2006) GLP-1 based therapy for type 2 diabetes. Eur. J. Pharm. Sci., 28, 96-108.
62. Ribel, U., Larsen, M.O., Rolin, B. et al. (2002) NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur. J. Pharmacol., 451, 217-225.
63. Toth, I., Malkinson, J.P., Flinn, N.S. et al. (1999) Novel lipoamino acid-and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. J. Med. Chem., 42, 4010-4013.
64. Toth, I., Flinn, N., Hillery, A. et al. (1994) Lipidic conjugates of luteinizing hormone releasing hormone (LHRH)+ and thyrotropin releasing hormone (TRH)+ that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells. Int. J. Pharm., 105, 241-247.
65. Flinn, N., Hussain, I., Shaw, A. et al. (1996) Oral absorption studies of lipid-polylysine conjugates of thyrotropin releasing hormone (TRH1) and luteinizing hormone releasing hormone (LHRH1). Int. J. Pharm., 138, 167-174.
66. Blanchfield, J.T., Gallagher, O.P., Cros, C. et al. (2007) Oral absorption and in vivo biodistribution of alfa-conotoxin MII and a lipidic analogue. Biochem. Bioph. Res. Co., 361, 97-102.
67. Foldvari, M., Attah-Poku, S., Hu, J. et al. (1998) Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery. J. Pharm. Sci., 87, 1203-1208.
68. Foldvari, M., Baca-Estrada, M.E., He, Z. et al. (1999) Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol. Appl. Biochem., 30 (Pt 2), 129-137.
69. Kellam, B., Drouillat, B., Dekany, G. et al. (1998) Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int. J. Pharm., 161, 55-64.
70. Gozes, I., Bardea, A., Reshef, A. et al. (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA, 93, 427-432.
71. Magdassi, S., Kamyshny, A. and Baszkin, A. (2001) Interfacial properties of hydrophobically modified biomolecules: fundamental aspects and applications. J. Disper. Sci. Technol., 22, 313-322.
72. Whittingham, J.L., Havelund, S. and Jonassen, I. (1997) Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry, 36, 2826-2831.
73. Olsen, H.B. and Kaarsholm, N.C. (2000) Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin. Biochemistry, 39, 11893-11900.
74. Yonemoto, W., McGlone, M.L. and Taylor, S.S. (1993) N-myristylation of the catalytic subunit of cAMP-dependent protein kinase conveys structural stability. J. Biol. Chem., 268, 2348-2352.
75. Traxler, K.W. and Dewey, T.G. (1994) Effects of depalmitoylation on physicochemical properties of rhodopsin. Biochemistry, 33, 1718-1723.
76. Kennedy, M.T., Brockman, H. and Rusnak, F. (1996) Contributions of myristoylation to calcineurin structure/function. J. Biol. Chem., 271, 26517-26521.
77. Wang, J. and Shen, W.C. (2000) Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice. Int. J. Pharm., 204, 111-116.
78. Delie, F., Couvreur, P., Nisato, D. et al. (1994) Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharm. Res., 11, 1082-1087.
79. Pignatello, R. and Pecora, T.M.G. (2007) Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity. Pharmazie, 62, 663-667.
80. Fahmy, T.M., Samstein, R.M., Harness, C.C. and Mark Saltzman, W. (2005) Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials, 26, 5727-5736.
81. Hecky, J. and Muller, K.M. (2005) Structural perturbation and compensation by directed evolution at physiological temperature leads to thermostabilization of beta-lactamase. Biochemistry, 44, 12640-12654.
82. Kotz, J.D., Bond, C.J. and Cochran, A.G. (2004) Phage-display as a tool for quantifying protein stability determinants. Eur. J. Biochem., 271, 1623-1629.
83. Bommarius, A.S., Broering, J.M., Chaparro-Riggers, J.F. and Polizzi, K.M. (2006) High-throughput screening for enhanced protein stability. Curr. Opin. Biotech., 17, 606-610.
84. Eijsink, V.G.H., Bj ø rk, A., Seidnes, S. et al. (2004) Rational engineering of enzyme stability. J. Biotechnol., 113, 105-120.
85. Eijsink, V.G.H., Seidnes, S., Borchert, T.V. and Van Den Burg, B. (2005) Directed evolution of enzyme stability. Biomol. Eng., 22, 21-30.
86. Marshall, S.A., Lazar, G.A., Chirino, A.J. and Desjarlais, J.R. (2003) Rational design and engineering of therapeutic proteins. Drug Discov. Today, 8, 221.
87. DeLano, W..L. (2002) T he PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, USA.
88. Chantalat, L., Jones, N.D., Korber, F. et al. (1995) The crystal structure of wild-type growth hormone at 2.5 Angstrom resolution. Protein Pept. Lett., 2, 333-340.
89. Zakrzewska, M., Krowarsch, D., Wiedlocha, A. and Otlewski, J. (2004) Design of fully active FGF-I variants with increased stability. Protein Eng. Des. Sel., 17, 603-611.
90. Dahiyat, B.I. and Mayo, S.L. (1996) Protein design automation. Protein Sci., 5, 895-903.
91. Dahiyat, B.I. and Mayo, S.L. (1997) De novo protein design: fully automated sequence selection . Science, 278, 82-87.
92. Dahiyat, B.I. and Mayo, S.L. (1997) Probing the role of packing specificity in protein design. Proc. Natl. Acad. Sci. USA, 94, 10172-10177.
93. Filikov, A.V., Hayes, R.J., Luo, P. et al. (2002) Computational stabilisation of human growth hormone. Protein Sci., 11, 1452-1461.
94. Luo, P., Hayes, R.J., Chan, C. et al. (2002) Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci., 11, 1218-1226.
95. Eidness, M.K., Richie, K.A., Burden, A.E. et al. (1997) Dissecting contributions to the thermostability of pyrococcus furiosus rubredoxin: b-sheet chimeras. Biochemistry, 36, 10406-10413.
96. Jiang, X., Bishop, E.J. and Farid, R.S. (1997) A de novo designed protein with properties that characterize natural hyperthermophilic proteins. J. Am. Chem. Soc., 119, 838-839.
97. Lee, B. and Vasumatzis, G. (1997) Stabilization of protein structures. Curr. Opin. Biotech., 8, 423-428.
98. Rees, D.C. and Adams, M.W.W. (1995) Hyperthermophiles: taking the heat and loving it. Structure, 3, 251-254.
99. Arakawa, T., Prestrelski, S.J., Narhi, L.O. et al. (1993) Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J. Protein Chem., 12, 525-531.
100. Lin, L. (1998) Betaseron, in Characterisation of Biotechnology Pharmaceutical Products (eds F. Brown, A. Lubiniecki and G. Murano), Karger, Basel, pp. 97-104.
101. Nishi, N., Itoh, A., Fujiyama, A. et al. (2005) Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett., 579, 2058-2064.
102. Malakauskas, S.M. and Mayo, S.L. (1998) Design, structure and stability of a hyperthermophilic protein variant. Nat. Struct. Biol., 5, 470-475.
103. Pantoliano, M.W., Ladner, R.C., Bryan, P.N. et al. (1987) Protein engineering of subtilisin BPN': enhanced stabilization through the introduction of two cysteines to form a disulfide bond. Biochemistry, 26, 2077-2082.
104. Kappelgaard, A.-M., Bojesen, A., Skydsgaard, K. et al. (2004) Hormone: preservatives and buffers. Horm. Res., 62, 98-103.
105. O'Conner, B.H. and Oeswein, J.Q. (1998) Human growth hormone aqueous formulation. Genentech Inc. US Patent 5,763,394.
106. Bethel, M.A. and Feinglos, M.N. (2005) Basal insulin therapy, in type 2 diabetes. J. Am. Board Fam. Pract., 18, 199-204.
107. Garg, S.K., Rosenstock, J. and Ways, K. (2005) Optimised basal-bolus insulin regimens in type 1 diabetes: insulin glusine versus regular human insulin in combination with basal insulin glargine. Endocr. Pract., 11, 11-17.
108. Brange, J. and Volund, A. (1999) Insulin analogs with improved pharmacokinetic profiles. Adv. Drug Deliver. Rev., 35, 307-335.
109. Becker, R.H.A. (2007) Insulin glusine complementing basal insulins: a review of structure and activity. Diabet. Technol. Ther., 9, 109-121.
110. Brange, J., Andersen, L., Laursen, E.D. and Meyn, G.R.E. (1997) Towards understanding insulin fibrillation. J. Pharm. Sci., 86, 517-525.